Cytokine Receptor-Like Factor 1 (CRLF1) Protects against 6-Hydroxydopamine Toxicity Independent of the gp130/JAK Signaling Pathway

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Looyenga, Brendan D ^a   Resau, James ^a   MacKeigan, Jeffrey P ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR RECEPTOR; CRLF1 PROTEIN; CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; JANUS KINASE; OXIDOPAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CRLF1 GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASES; MICROSCOPY, FLUORESCENCE; NEUROBLASTOMA; OXIDOPAMINE; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRETINOIN;

EID: 84879274439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066548     Document Type: Article

References (45)

1. Lin MT, Beal MF, (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
2. Banerjee R, Starkov AA, Beal MF, Thomas B, (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792: 651-663.
3. Lu T, Pan Y, Kao SY, Li C, Kohane I, et al. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891.
4. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
5. Dick FD, (2006) Parkinson's disease and pesticide exposures. Br Med Bull 79-80: 219-231.
6. Miyazaki I, Asanuma M, (2009) Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem Res 34: 698-706.
7. Choi HJ, Lee SY, Cho Y, Hwang O, (2005) Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem Int 46: 329-335.
8. Graham DG, (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643.
9. Zigmond MJ, Berger TW, Grace AA, Stricker EM, (1989) Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol Chem Neuropathol 10: 185-200.
10. Ungerstedt U (1971) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367: 95-122.
11. Deumens R, Blokland A, Prickaerts J, (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175: 303-317.
12. Opacka-Juffry J, Wilson AW, Blunt SB, (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 810: 27-33.
13. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL, (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29: 699-701.
14. Collier TJ, Steece-Collier K, McGuire S, Sortwell CE, (2003) Cellular models to study dopaminergic injury responses. Ann N Y Acad Sci 991: 140-151.
15. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS, (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751-3757.
16. Ross RA, Spengler BA, Biedler JL, (1983) Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 71: 741-747.
17. Lopes FM, Schroder R, da Frota ML Jr, Zanotto-Filho A, Muller CB, et al. (2010) Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res 1337: 85-94.
18. Pahlman S, Mamaeva S, Meyerson G, Mattsson ME, Bjelfman C, et al. (1990) Human neuroblastoma cells in culture: a model for neuronal cell differentiation and function. Acta Physiol Scand Suppl 592: 25-37.
19. Tirmenstein MA, Hu CX, Scicchitano MS, Narayanan PK, McFarland DC, et al. (2005) Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicol In Vitro 19: 471-479.
20. Pahlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T, (1984) Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 14: 135-144.
21. Pahlman S, Hoehner JC, Nanberg E, Hedborg F, Fagerstrom S, et al. (1995) Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 31A: 453-458.
22. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, et al. (2009) Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30: 127-135.
23. Gomez-Lazaro M, Bonekamp NA, Galindo MF, Jordan J, Schrader M, (2008) 6-Hydroxydopamine (6-OHDA) induces Drp1-dependent mitochondrial fragmentation in SH-SY5Y cells. Free Radic Biol Med 44: 1960-1969.
24. Kort EJ, Norton P, Haak P, Berghuis B, Ramirez S, et al. (2009) Review paper: Gene expression profiling in veterinary and human medicine: overview of applications and proposed quality control practices. Vet Pathol 46: 598-603.
25. Joshi S, Guleria RS, Pan J, Dipette D, Singh US, (2007) Heterogeneity in retinoic acid signaling in neuroblastomas: Role of matrix metalloproteinases in retinoic acid-induced differentiation. Biochim Biophys Acta 1772: 1093-1102.
26. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, et al. (2007) Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 67: 3171-3176.
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
28. Kestler DP, Foster JS, Macy SD, Murphy CL, Weiss DT, et al. (2008) Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms. Mol Med 14: 318-326.
29. Elson GC, Lelievre E, Guillet C, Chevalier S, Plun-Favreau H, et al. (2000) CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci 3: 867-872.
30. Senaldi G, Varnum BC, Sarmiento U, Starnes C, Lile J, et al. (1999) Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A 96: 11458-11463.
31. Crisponi L, Crisponi G, Meloni A, Toliat MR, Nurnberg G, et al. (2007) Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type 1. Am J Hum Genet 80: 971-981.
32. Dagoneau N, Bellais S, Blanchet P, Sarda P, Al-Gazali LI, et al. (2007) Mutations in cytokine receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromes. Am J Hum Genet 80: 966-970.
33. Knappskog PM, Majewski J, Livneh A, Nilsen PT, Bringsli JS, et al. (2003) Cold-induced sweating syndrome is caused by mutations in the CRLF1 gene. Am J Hum Genet 72: 375-383.
34. Kaur N, Lu B, Monroe RK, Ward SM, Halvorsen SW, (2005) Inducers of oxidative stress block ciliary neurotrophic factor activation of Jak/STAT signaling in neurons. J Neurochem 92: 1521-1530.
35. Elson GC, Graber P, Losberger C, Herren S, Gretener D, et al. (1998) Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family. J Immunol 161: 1371-1379.
36. Burbulla LF, Kruger R, (2011) Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J Neurol Sci 306: 1-8.
37. Collier TJ, Kanaan NM, Kordower JH, (2011) Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci 12: 359-366.
38. Rubinsztein DC, (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443: 780-786.
39. Rousseau F, Gauchat JF, McLeod JG, Chevalier S, Guillet C, et al. (2006) Inactivation of cardiotrophin-like cytokine, a second ligand for ciliary neurotrophic factor receptor, leads to cold-induced sweating syndrome in a patient. Proc Natl Acad Sci U S A 103: 10068-10073.
40. Herholz J, Meloni A, Marongiu M, Chiappe F, Deiana M, et al. (2011) Differential secretion of the mutated protein is a major component affecting phenotypic severity in CRLF1-associated disorders. Eur J Hum Genet 19: 525-533.
41. Alexander WS, Rakar S, Robb L, Farley A, Willson TA, et al. (1999) Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr Biol 9: 605-608.
42. DeChiara TM, Vejsada R, Poueymirou WT, Acheson A, Suri C, et al. (1995) Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell 83: 313-322.
43. Gregg C, Weiss S, (2005) CNTF/LIF/gp130 receptor complex signaling maintains a VZ precursor differentiation gradient in the developing ventral forebrain. Development 132: 565-578.
44. Shimazaki T, Shingo T, Weiss S, (2001) The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. J Neurosci 21: 7642-7653.
45. Hagg T, Varon S, (1993) Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci U S A 90: 6315-6319.